Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 3/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PNP | P00491 | 4/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21332729 | 0.77 | PARP1 (0.50) | AOC3XDHLTB4RPARP1PNP | |
| SCHEMBL9878574 | 0.76 | POLB (0.61) | XDHPARP1SMN1; SMN2ADORA1HCAR2 | |
| SCHEMBL5907152 | 0.73 | BACE1 (0.74) | XDHLTB4RPNPBACE1 | |
| SCHEMBL3723702 | 0.73 | BACE1 (0.44) | XDHPARP1PNPBACE1ADORA1 | |
| SCHEMBL12598581 | 0.72 | AOC3 (1.00) | AOC3XDHLTB4RPARP1PNP | |
| SCHEMBL10843644 | 0.70 | XDH (0.54) | XDHPARP1ADORA1 | |
| SCHEMBL9879243 | 0.70 | BACE1 (0.54) | XDHBACE1SMN1; SMN2ADORA1HCAR2 | |
| SCHEMBL9879095 | 0.70 | MEN1 (0.54) | SMN1; SMN2ADORA1DAO | |
| SCHEMBL12956835 | 0.70 | PNP (0.62) | XDHLTB4RPNPSMN1; SMN2DHFR | |
| SCHEMBL7106470 | 0.69 | PARP1 (0.65) | PARP1SMN1; SMN2ADORA1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716961-B | Self-complementary quadruple hydrogen bond supermolecule hot melt adhesive and synthesis method thereof | 郑州大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-114716961-A | Self-complementary quadruple hydrogen bond supramolecular hot melt adhesive and synthesis method thereof | 郑州大学 | 2022-07-08 | — | — | CN | disclosed |
| US-20060106044-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | IDENIX PHARMACEUTICALS INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20040092539-A1 | Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them | COLLA PAOLO LA (IT) | 2004-05-13 | — | — | US | disclosed |
| US-20030225114-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4- oxopyrimidines | IDENIX PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6635636-B1 | Reverse transcriptase inhibitors; human immunodeficiency virus and acquired immune deficiency syndrome | IDENIX PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-6545007-B2 | Topically applying to the skin or epithelial tissue of a human an effective amount of a dihydro-alkyloxy-benzyl-oxopyrimidine compound for inhibiting sexual transmission of HIV | IDENIX (CAYMAN) LIMITED (KY) | 2003-04-08 | — | — | US | disclosed |
| US-20030008887-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | IDENIX PHARMACEUTICALS INC. | 2003-01-09 | — | — | US | disclosed |
| EP-1098887-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Novirio Pharmaceuticals Limited (KY) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000003998-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-01-27 | — | — | WO | disclosed |
| WO-1991018887-A1 | DIAMINOPYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106044-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | DUT, UNG, NUDT1 | AOC3 571/4885XDH 240/4885LTB4R 3107/4885 |
| US-20030008887-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | DUT, UNG, NUDT1 | AOC3 499/4885XDH 258/4885LTB4R 2820/4885 |
| US-20040092539-A1 | Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them | TYMP, UMPS, TYMS | AOC3 1537/4885XDH 48/4885LTB4R 2628/4885 |
| US-20030225114-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4- oxopyrimidines | DUT, UNG, NUDT1 | AOC3 499/4885XDH 258/4885LTB4R 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.